A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-22. Anything still debated is marked as such rather than presented as settled.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
=== Discussed health risks === Like other foods, the consumption of edible insects could present health risks stemming from biological, toxicological, and allergenic hazards. Biological hazards include bacteria, viruses, protozoa, fungi and mycotoxins; toxological risks are poisons, pesticides, heavy metals and antinutrients; allergenic hazards relate to arginine kinase, tropomyosin and α-Amylase. Additionally, recent studies have indicated that proteins from yellow mealworm (Tenebrio molitor) may act as allergens, potentially triggering immunoglobulin E (IgE)-mediated allergic reactions and cross-reactivity, especially in individuals already sensitized to crustaceans or other arthropods. Chitin, a component of insect exoskeletons and other body parts, induces cytokine production in the digestive systems of humans and other mammals. Enzymes break the chitin down into smaller fragments, which trigger an immune response that results in inflammatory and allergic reactions. The human immune response to chitin is thought to be related to the abundance of dust mites as a cause of airway inflammatory disease and parasites as a cause of numerous diseases. In general, insects harvested from the wild pose a greater risk than farmed insects, and insects consumed raw pose a greater risk than insects that are cooked before consumption. Feed substrate and growing conditions are the main factors influencing the microbiological and chemical hazards of farmed insects.
antibiotic resistance gene A gene that confers resistance to one or more specific antibiotic compounds. In molecular cloning, plasmid vectors are often designed to carry antibiotic resistance genes as selectable markers alongside other genes of interest, because it permits the artificial selection of successfully transformed cell populations when the cells are cultured in the presence of the antibiotic.
== Properties == LCRs are more abundant in eukaryotes, but they also have a significant presence in many prokaryotes. On average, 0.05 and 0.07% of the bacterial and archaeal proteomes (total amino acids of LCRs in a given proteome/total amino acids of that proteome) form LCRs whereas for five model eukaryotic proteomes (human, fruitfly, yeast, fission yeast, Arabidopsis) this coverage was significantly higher (on average, 0.4%; between 2 and 23 times higher than prokaryotes). Eukaryotic LCRs tend to be longer than prokaryotic LCRs. The average size of a eukaryotic LCR is 42 amino acids long, whereas bacterial, archaeal and phage LCRs are 38, 36 and 33 amino acids long, respectively. In the Archaea, the halobacterium Natrialba magadii has the highest number of LCRs and the highest enrichment for LCRs. In Bacteria, Enhygromyxa salina, a delta proteobacterium that belongs to myxobacteria has the highest number of LCRs and the highest enrichment for LCRs. Intriguingly, four of the top five bacteria with the highest enrichment for LCRs are also myxobacteria. The three most enriched amino acids within LCRs of Bacteria are proline, glycine and alanine, whereas in Archaea they are threonine, aspartate and proline. In Phages, they are alanine, glycine and proline. Glycine and proline emerge as very enriched amino acids in all three evolutionary lineages, whereas alanine is highly enriched in Bacteria and Phages but not enriched in Archaea.
Sources: en.wikipedia.org
=== POMC === POMC produced from the melanotropes of the pars intermedia is cleaved into adrenocorticotropic hormone (ACTH) and β-lipotropin (β-LPH). The majority of ACTH is then cleaved into α-MSH and corticotropin-like intermediate peptide (CLIP). CLIP is thought to have an influence on subsequent insulin resistance that can be seen in PPID horses. ACTH is also produced by corticotropes in the pars distalis of the equine pituitary. In a normal horse, this accounts for the majority of ACTH production. ACTH produced by the pars distalis is subject to negative feedback in a normal horse, so high cortisol levels reduce ACTH production by the pituitary, subsequently reducing cortisol levels. In a horse with PPID, ACTH levels are high as a result of pars intermedia production, but it is not subject to negative feedback regulation. Despite the high levels of ACTH, cortisol levels vary, and are sometimes lower than normal. Additionally, hyperplasia of the adrenal cortex is infrequent. The role of ACTH is, therefore, still poorly understood.
== Sources == Aristotle. Metaphysics Nicomachean Ethics On the Soul. Physics Caston, Victor. "Aristotle's Psychology". A Companion to Ancient Philosophy. Ed. Mary Gill and Pierre Pellegrin. Hoboken: Wiley-Blackwell, 2006. 316–46. "Aristotle's Two Intellects: A Modest Proposal". Phronesis 44.3 (1999): 199–227. Cross, Richard. The Physics of Duns Scotus. Oxford: Oxford UP, 1998. Eberl, Jason T. "Aquinas on the Nature of Human Beings." The Review of Metaphysics 58.2 (November 2004): 333–65. Gilson, Étienne. The Philosophy of St. Bonaventure. Trans. F. J. Sheed. NY: Sheed & Ward, 1938. Irwin, Terence. Aristotle's First Principles. Oxford: Oxford UP, 1990. Keck, David. Angels & Angelology in the Middle Ages. NY: Oxford UP, 1998. Kenny, Anthony. Aquinas on Mind. London: Routledge, 1993. Leftow, Brian. "Souls Dipped in Dust." Soul, Body, and Survival: Essays on the Metaphysics of Human Persons. Ed. Kevin Corcoran. NY: Cornell UP, 2001. 120–38. "Soul, Mind, and Brain." The Waning of Materialism. Ed. Robert C. Koons and George Bealer. Oxford: Oxford UP, 2010. 395–417. McEvilley, Thomas. The Shape of Ancient Thought. NY: Allworth, 2002. Mendell, Henry. "Aristotle and Mathematics". Stanford Encyclopedia of Philosophy. 26 March 2004. Stanford University. 2 July 2009 <http://plato.stanford.edu/entries/aristotle-mathematics/>. Normore, Calvin. "The Matter of Thought". Representation and Objects of Thought in Medieval Philosophy. Ed. Henrik Lagerlund. Hampshire: Ashgate, 2007. 117–133. Pasnau, Robert. Thomas Aquinas on Human Nature. Cambridge: Cambridge UP, 2001. Robinson, Timothy.
=== Biomaterials and nanotechnology === Mechler engaged in the design and characterization of biomaterials, nanostructures as well as in the development of novel nanotechnologies throughout his career. He used multimodal atomic force microscopy to map charge transfer properties of the conductive copolymer poly(ethyldioxythiophene)–poly(styrenesulfonic acid), showing that efficient charge injection occurs at lamellar edges and can be improved by controlling lamellar orientation. In a collaborative project, he also presented a method utilizing surface acoustic waves to produce monodispersed submicron poly-ε-caprolactone particles, demonstrating how acoustic forces and evaporative processes influence particle size and morphology. In a joint study, Mechler established that 14-helical N-acetyl β3-peptides self-assemble into nanofibers and that their morphology, such as nano-beams and dendritic structures, can be tuned by adjusting the solvent and inter-fibril interactions, enabling new bio- and nanomaterial applications. By using far-IR spectroscopy and DFT modeling, he confirmed the structure of self-assembled fibrous nano-materials from unnatural tripeptides, showing that far-IR spectroscopy can effectively characterize bioinspired materials where crystallographic methods fall short. He further showcased that using two binding motifs in supramolecular assemblies creates metallosupramolecular frameworks with controlled nanorod and two-dimensional structures, with copper ions forming polynuclear metal complexes.
{\displaystyle \sigma _{11}=\left(\lambda ^{2}-{\cfrac {1}{\lambda ^{2}}}\right)\left({\cfrac {\mu J_{m}}{J_{m}-I_{1}+3}}\right)~;~~\sigma _{22}=0~;~~\sigma _{33}=\left(1-{\cfrac {1}{\lambda ^{2}}}\right)\left({\cfrac {\mu J_{m}}{J_{m}-I_{1}+3}}\right)~.}
Sources: en.wikipedia.org
=== Organoeinsteinium compounds === Einsteinium's high radioactivity has a potential use in radiation therapy, and organometallic complexes have been synthesized in order to deliver einsteinium to an appropriate organ in the body. Experiments have been performed on injecting einsteinium citrate (as well as fermium compounds) to dogs. Einsteinium(III) was also incorporated into β-diketone chelate complexes, since analogous complexes with lanthanides previously showed strongest UV-excited luminescence among metallorganic compounds. When preparing einsteinium complexes, the Es3+ ions were 1000 times diluted with Gd3+ ions. This allowed reducing the radiation damage so that the compounds did not disintegrate during the 20 minutes required for the measurements. The resulting luminescence from Es3+ was much too weak to be detected. This was explained by the unfavorable relative energies of the individual constituents of the compound that hindered efficient energy transfer from the chelate matrix to Es3+ ions. Similar conclusion was drawn for americium, berkelium and fermium. Luminescence of Es3+ ions was however observed in inorganic hydrochloric acid solutions as well as in organic solution with di(2-ethylhexyl)orthophosphoric acid. It shows a broad peak at about 1064 nanometers (half-width about 100 nm) which can be resonantly excited by green light (ca. 495 nm wavelength). The luminescence has a lifetime of several microseconds and the quantum yield below 0.1%.
Importantly, this results in a mixture of comic effects and of a serious aspiration to reflect on the continuing relevance of gender roles in the 21st century. The text can thus also be read as a literary plea for overcoming narrowly conceived identity politics and identity-based divisions.
Some clinical tests require clinical chemists to process the specimen before testing. Clinical chemists and medical laboratory scientists serve as the interface between the laboratory side and the clinical practice, providing suggestions to physicians on which test panel to order and interpret any irregularities in test results that reflect on the patient's health status and organ system functionality. This allows healthcare providers to make more accurate evaluation of a patient's health and to diagnose disease, predicting the progression of a disease (prognosis), screening, and monitoring the treatment's efficiency in a timely manner. The type of test required dictates what type of sample is used.
=== Changing medical practices === Atenolol has been given as an example of how slow healthcare providers are to change their prescribing practices in the face of medical evidence that indicates that a drug is not as effective as others in treating some conditions. In 2012, 33.8 million prescriptions were written to American patients for this drug. In 2014, it was in the top (most common) 1% of drugs prescribed to Medicare patients. Although the number of prescriptions has been declining steadily since limited evidence articles contesting its efficacy was published, it has been estimated that it would take 20 years for doctors to stop prescribing it for hypertension. Despite its diminished efficacy when compared to newer antihypertensive drugs, atenolol and other beta blockers are still a relevant clinical choice for treating some conditions, since beta blockers are a diverse group of medicines with different properties that still requires further research. As a consequence, reasons for the continued popularity of beta blockers cannot be fully attributed to a slow healthcare system – patient compliance factors, such as treatment cost and duration, also affect adherence and popularity of therapy.
Synthesis of pharmaceuticals, flavors and fragrances, agrochemicals, nutraceuticals, fine chemicals, bulk monomers and biofuels. Animal feed, e.g. phytase for utilization of organically bound phosphate by pigs and poultry. Food and beverage processing, e.g. lipases in cheese manufacture and laccase in wine clarification. Cosmetics, e.g. in skin care products Oils and fats processing, e.g. in biolubricants, bioemulsifiers, bio-derived emollients. Carbohydrate processing, e.g. laccase in carbohydrate oxidations. Pulp and paper, e.g. in pulp bleaching. Detergents, e.g. proteases, amylases and lipases for removal of protein, carbohydrate and fat stains. Waste water treatment, e.g. for removal of phenols, dyes, and endocrine disrupters. Biosensors/diagnostics, e.g. glucose oxidase and cholesterol oxidase biosensors. Delivery of proteins as therapeutic agents or nutritional/digestive supplements e.g. beta-galactosidase for digestive hydrolysis of lactose in dairy products to alleviate the symptoms of lactose intolerance.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.